Market Report Source

Overview

Introduction
Palatin Technologies’ bremelanotide (PT-141) is a novel melanocortin receptor agonist that is believed to be the only agent currently in development for the treatment of both erectile dysfunction (ED) and female sexual dysfunction (FSD).

Scope
Explores the regulatory and commercial potential for PTN’s bremelanotide, a novel agent in development for male and female sexual dysfunction
Interviews with 7 urologists familiar with bremelanotide and its clinical data and potential for the treatment of male and female sexual dysfunction

Highlights
While there would appear to be much potential for an agent that can improve libido in both male and female patients without acting directly on the vascular system, we believe that unclear efficacy of PTN’s bremelanotide and substantial regulatory risk diminish the potential this agent in the treatment of male and female sexual dysfunction.

Pending results from the two Phase IIb trials which are expected later this year, we forecast US bremelanotide revenues well below the blockbuster potential estimated by some Wall Street analysts.

Reasons to Purchase
Understand the commercial potential for Palatin Technologies’ Bremelanotide through in-depth analysis based on interviews with leading experts
Anticipate likely changes in the future market dynamics for erectile dysfunction therapies if approval of bremelanotide occurs”

Table of Contents

SUMMARY

Competition and regulatory risk cloud potential for PTN’s Bremelanotide

PALATIN TECHNOLOGIES

Overview

Bremelanotide (PT-141)

ERECTILE DYSFUNCTION

Overview

Despite widely popular options, unmet need still exists

Novel melanocortin agonist shows promise in the treatment of ED

Potential in female sexual dysfunction could be an important differentiating factor

FACTORS AFFECTING THE POTENTIAL FOR BREMELANOTIDE

Stiff competition and unclear efficacy diminish bremelanotide’s potential in ED

High placebo-effect that has plagued historical ED trials could slow path to market

Use in combination with PDE-5 inhibitors viewed as intriguing

Unclear benchmarks could slow development for female sexual dysfunction

DATAMONITOR BREMELANOTIDE FORECAST

Despite growing market, annual cost of therapy estimates appear overstated

Bremelanotide could find niche in patients who do not respond to PDE-5 inhibitors

Slow development road raises questions about bremelanotide’s potential

Off-label use in female sexual dysfunction patients could boost revenues

APPENDIX

Supplementary data

Datamonitor Healthcare

Disclosure information

Ask the analyst

List of Tables

Table 1: Estimated US bremelanotide revenues 2009-2013

Table 2: US erectile dysfunction model 14